Newsletter | March 29, 2021

03.29.21 -- Scalable Manufacturing Of Adeno Viral Vector For Gene Therapy

How To Prepare For Future Viral Vector Manufacturing Technologies And Platforms

The challenges and shortage of vector production reflects the fact that these materials and products are experiencing strong clinical success. Let’s celebrate the reason for this demand. To meet it, we need to industrialize and rethink how we transition from what has historically been carried out in translational clinical centers at smaller scale, using flasks and open systems, towards commercial production and methodologies.

Purifying Plasmid DNA Using A Modern Chromatography Resin

As products progress through clinical phases there is a greater need for scalable plasmid DNA production, which must first be manufactured and purified in a GMP facility or high-quality plasmid DNA production areas. This has led to pressure on manufacturers to create the capacity and resources essential to meet the rising demand for high-quality plasmid DNA.

Strategies To Address The Viral Vector Manufacturing Shortage

Companies pursuing gene therapies, and even CDMOs that want to partner with them, must figure out a way to close the gap in viral vector production. For many, this means facing a build versus buy capacity decision that has long been a part of the biomanufacturing landscape, but procuring viral vector capacity comes with even more complexity and risk.

On-Demand Webinar
Designing Efficiency Into Your AAV Process

To meet your demand for high-quality adeno-associated virus (AAV) now and in the future you need a scalable and cost-effective way to make it. Adapt this efficient process that we developed by optimizing each step from suspension cell culture to purified bulk.

In The News
Large-Scale AAV For Preclinical Gene Therapy Studies

Cytiva and the University of Massachusetts Medical School (UMMS) announced their intent to establish a large-scale viral vector manufacturing facility to provide high-quality recombinant adeno-associated virus (AAV) vectors for preclinical research. This partnership aims to accelerate novel gene therapies to patients.